DJIA 17,810.06 91.06 0.51%
NASDAQ 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
market minute promo

MannKind Corp (NASDAQ: MNKD)



company name or ticker

US IPO Weekly Recap: Burgers and bionic eyes gain over 100% as 9 companies go public

Sanofi's New Medicines Seminar: Implications For Afrezza

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Second Sight sees double: Year's 6th IPO to soar 100% on day one

Sanofi: Recent Plunge Is A Buying Opportunity

Benzinga's Top #PreMarket Gainers

Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind

Is this MannKind Corporation's Worst Nightmare?

MannKind's long-awaited inhaled insulin product is nearing a commercial launch. The drug may be in for a bumpier ride than most expect, however. Here's why.

MannKind's (MNKD) CEO Alfred Mann on Q3 2014 Results - Earnings Call Transcript

MannKind Is On The Mend

See More Articles...